

**North of Tyne, Gateshead and North Cumbria
Area Prescribing Committee**
www.northoftyneapc.nhs.uk
Tuesday 7th July 2020 12:30 pm
Microsoft TEAMS meeting
[Join Microsoft Teams Meeting](#)

AGENDA

1.	Apologies for absence	
2.	Declarations of interest	
3.	Review of terms of reference	Enc.1.
4.	Election of officers deferred from April meeting	Enc.2.
5.	Appeals against previous decisions None	
6.	Minutes from April	Enc.3.
7.	Matters arising not on the agenda	
8.	APC Action log	Enc.4.
9.	Report from the Formulary sub-group – meeting cancelled <ul style="list-style-type: none"> • Betesil®(Betamethasone valerate 0.1% Medicated Plaster): application considered by email correspondence. The FSC recommend rejection on grounds of cost effectiveness, with concerns that the evidence base is poor and the comparator (non-occlusive treatment) doesn't enable cost-comparison with tape already on formulary. 	Enc.5.
10.	Report from the Medicines Guidelines and Use Group – meeting cancelled but submissions were received and reviewed virtually. The following recommendations are made: Guidance for approval: <ul style="list-style-type: none"> • Ketamine in palliative care - update • Vitamin B12 guidance – minor update to remove reference to liver stores • Catheter formulary v2 Guidance to reinstate: <ul style="list-style-type: none"> • North of Tyne/Gateshead guidelines for detection, management and referral of adults with kidney disease. Guidance to retire: <ul style="list-style-type: none"> • Menopause guidance To note: NICE rapid guidance and evidence summaries specific to COVID-19. https://www.nice.org.uk/covid-19	Enc.6. Enc.7. Enc.8.
11.	Opiate/pain management sub-group <ul style="list-style-type: none"> • Data to end Qtr 4 19.20 	Enc.9.

12.	<p>RMOCs No update</p>	
13.	<p>Northern (NHS) Treatment Advisory Group (NTAG). http://ntag.nhs.uk/</p> <p>The following recommendations were finalised by NTAG at their meeting on the 2nd June 2020 and are now available on the website:</p> <ul style="list-style-type: none"> • Infliximab Subcutaneous (Remsima[®]) • Verteporfin (Visudyne[®]) with photo-dynamic therapy for chronic central serous chorioretinopathy • Vaginal devices for female urinary stress incontinence • Purewick[®] female external urinary catheter <p>The following recommendation was updated by NTAG and is now available on the website:</p> <ul style="list-style-type: none"> • Sativex[®] for the treatment of non-MS pain <p>The following recommendations were archived by NTAG as they are now superseded by NICE TA or NHSE guidance:</p> <ul style="list-style-type: none"> • Cervical spinal prosthetic disc replacement for degenerative cervical disc disease (NETAG) • Tocilizumab (RoActemra[®]) for systemic-onset and polyarticular juvenile idiopathic arthritis (NETAG) • Bosentan (Tracleer[®]) for digital ulcers (NETAG) • Novel fentanyl products (Abstral[®], Effentora[®] Instanyl[®] and PecFent[®]): Updated appraisal for breakthrough pain associated with cancer (NETAG) 	<p>Enc.10. Enc.11.</p> <p>Enc.12 Enc.13.</p> <p>Enc.14.</p>
14.	<p>NICE Technology Appraisals published since last meeting</p> <ul style="list-style-type: none"> • TA626 Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure • TA627 Lenalidomide with rituximab for previously treated follicular lymphoma • TA628 Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer • TA629 Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab • TA630 Larotrectinib for treating NTRK fusion-positive solid tumours • TA631 Fremanezumab for preventing migraine • TA632 Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer • TA633 Ustekinumab for treating moderately to severely active ulcerative colitis • TA634 Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) • TA635 Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) • TA636 Eculizumab for treating refractory myasthenia gravis (terminated appraisal) • TA637 Ranibizumab for treating diabetic retinopathy (terminated appraisal) 	

15.	<p>NHS England</p> <ul style="list-style-type: none"> • EAMS approval for remdesivir in COVID-19 https://www.gov.uk/government/news/mhra-supports-the-use-of-remdesivir-as-the-first-medicine-to-treat-covid-19-in-the-uk?utm_source=4307a5df-53f5-408b-bcf6-fcd2adddd655&utm_medium=email&utm_campaign=govuk-notifications&utm_content=immediate • Specialised Services circulars <ul style="list-style-type: none"> ○ SSC2133 NICE Technology Appraisal Final Appraisal Determination - obinutuzumab with bendamustine for treating follicular lymphoma after rituximab ○ SSC2134 NICE Technology Appraisal Final Appraisal Determination: lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer ○ SSC2136 Clinical Commissioning Policy: Temozolomide as adjuvant treatment for people with newly diagnosed anaplastic astrocytoma without 1p/19q codeletion following surgery and radiotherapy (Adults) ○ SSC2137 Clinical Commissioning Policy: Dexrazoxane for preventing cardiotoxicity in children and young people (< 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer ○ SSC2138 Specialised Blood Disorder Policies: Factor X and Vonicog Alfa ○ SSC2139 NICE Technology Appraisal Final Appraisal Determination: larotrectinib for treating NTRK fusion-positive solid tumours ○ SSC2140 Canakinumab for periodic fever syndromes (all ages) ○ SSC2143 NICE Technology Appraisal Final Appraisal Determination: atezolizumab with nab-paclitaxel for treating PD-L1-positive, triple-negative, advanced breast cancer ○ SSC2144 - NICE Technology Appraisal Final Appraisal Determination - atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ○ SSC2148 - Nivolumab as monotherapy treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal, squamous cell carcinoma (OSCC) after one prior fluoropyrimidine and platinum-based chemotherapy 	<p>Enc.15.</p> <p>Enc.16.</p>
16.	Chairman's action	
17.	Any other business	
18.	<p>Date, time and venue of next meetings: Cobalt conference centre, Level 2 Northumbria Healthcare NHS Foundation Trust Northumbria House 7-8 Silver Fox Way Cobalt Business Park North Shields NE27 0QJ Tuesday, 13th October 2020 12:30 pm (room to confirm) Tea/coffee will be available from 12:15 pm</p>	